Anemia Had No Effect on Efficacy Outcomes in Treatment-NaiVE Patients Who Received Telaprevir-Based Regimen in the Advance and Illuminate Phase 3 Studies

被引：0
|
作者：
Poordad, Fred
Sulkowski, Mark
Reddy, Rajender
Di Bisceglie, Adrian M.
Zeuzem, Stefan
Afdhal, Nezam
Bengtsson, Leif
Wright, Christopher I.
Kauffman, Robert S.
Adda, Nathalie
机构：
来源：
GASTROENTEROLOGY | 2011年 / 140卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S898 / S899
页数：2
相关论文
共 31 条
  • [1] ANEMIA HAD NO EFFECT ON EFFICACY OUTCOMES IN TREATMENT-NAIVE PATIENTS WHO RECEIVED TELAPREVIR-BASED REGIMEN IN THE ADVANCE AND ILLUMINATE PHASE 3 STUDIES
    Sulkowski, M. S.
    Reddy, R.
    Afdhal, N. H.
    Di Bisceglie, A. M.
    Zeuzem, S.
    Poordad, F.
    Bengtsson, L.
    Wright, C. I.
    Kauffman, R. S.
    Adda, N.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S195 - S195
  • [2] Impact of Telaprevir-Based Treatment Regimens on Fatigue in Genotype 1 HCV Treatment-NaiVE Patients: Results From Advance and Illuminate Studies
    Muir, Andrew J.
    Gavan, Sandra
    Thal, Gary
    Nuyts, Guy
    McCallister, Scott
    Beumont-Mauviel, Maria
    Luo, Don
    Adda, Nathalie
    Wright, Christopher I.
    Sherman, Kenneth E.
    GASTROENTEROLOGY, 2011, 140 (05) : S944 - S945
  • [3] IMPACT OF TELAPREVIR-BASED TREATMENT REGIMENS ON FATIGUE IN GENOTYPE 1 HCV TREATMENT-NAIVE PATIENTS: RESULTS FROM ADVANCE AND ILLUMINATE STUDIES
    Gavart, S.
    Sherman, K. E.
    Thal, G.
    Nuyts, G.
    McAllister, S.
    Beumont, M.
    Luo, D.
    Adda, N.
    Wright, C.
    Muir, A. J.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S477 - S477
  • [4] WORK PRODUCTIVITY AMONG GENOTYPE 1 HEPATITIS C VIRUS (HCV) TREATMENT-NAIVE PATIENTS RECEIVING TELAPREVIR-BASED TREATMENT REGIMENS: RESULTS FROM ADVANCE AND ILLUMINATE STUDIES
    Thal, G.
    Nuyts, G.
    Mcallister, S.
    Luo, D.
    Muir, A. J.
    Sherman, K. E.
    Adda, N.
    Wright, C.
    Beumont, M.
    Gavart, S.
    VALUE IN HEALTH, 2011, 14 (03) : A184 - A184
  • [5] Ribavirin dose modification in treatment-naive and previously treated patients who received telaprevir combination treatment: no impact on sustained virologic response in Phase 3 studies
    Roberts, Stuart
    Sulkowski, Mark S.
    Afdhal, Nezam
    Andreone, Pietro
    Diago, Moises
    Pol, Stanislas
    Poordad, Fred
    Zeuzem, Stefan
    Bengtsson, Leif
    Luo, Don
    Adda, Nathalie
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 179 - 179
  • [6] Ribavirin Dose Modification in Treatment-NaiVE and Previously Treated Patients Who Received Telaprevir Combination Treatment: No Impact on Sustained Virologic Response in Phase 3 Studies
    Sulkowski, Mark
    Roberts, Stuart K.
    Afdhal, Nezam H.
    Andreone, Pietro
    Diago, Moises
    Pol, Stanislas
    Poordad, Fred
    Zeuzem, Stefan
    Bengtsson, Leif
    Luo, Don
    Witek, James
    Adda, Nathalie
    GASTROENTEROLOGY, 2012, 142 (05) : S919 - S919
  • [7] RIBAVIRIN DOSE MODIFICATION IN TREATMENT-NAIVE AND PREVIOUSLY TREATED PATIENTS WHO RECEIVED TELAPREVIR COMBINATION TREATMENT: NO IMPACT ON SUSTAINED VIROLOGIC RESPONSE IN PHASE 3 STUDIES
    Sulkowski, M. S.
    Roberts, S.
    Afdhal, N.
    Andreone, P.
    Diago, M.
    Pol, S.
    Poordad, F.
    Zeuzem, S.
    Bengtsson, L.
    Luo, D.
    Witek, J.
    Adda, N.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S459 - S460
  • [8] NO IMPACT OF INSULIN RESISTANCE ON ANTIVIRAL EFFICACY OF TELAPREVIR-BASED REGIMEN IN HCV GENOTYPE 1 TREATMENT-NAIVE PATIENTS: SUB-ANALYSIS OF C208 STUDY
    Serfaty, Lawrence
    Forns, Xavier
    Goeser, Tobias
    Ferenci, Peter
    Nevens, Frederik
    Carosi, Giampiero
    Drenth, Joost P.
    Lonjon-Domanec, Isabelle
    DeMasi, Ralph
    Picchio, Gaston
    Beumont, Maria
    Marcellin, Patrick
    HEPATOLOGY, 2010, 52 (04) : 705A - 705A
  • [9] Impact of insulin resistance on antiviral efficacy of telaprevir-based regimen in treatment-naive genotype 1 HCV: Results from C208 sub-analysis
    Carosi, G.
    Colombo, M.
    Spinetti, A.
    Zaltron, S.
    Serfaty, L.
    Marcellin, P.
    Lonjon-Domanec, I.
    DeMasi, R.
    Beumont, M.
    DIGESTIVE AND LIVER DISEASE, 2011, 43 : S84 - S84
  • [10] Telaprevir in Combination with Peginterferon and Ribavirin in Genotype 1 HCV Treatment-Naive Patients: Final Results of Phase 3 ADVANCE Study
    Ferenci, Peter
    Jacobson, Ira M.
    Adda, Nathalie
    Bengtsson, Leif
    George, Shelley
    Kauffman, Robert
    Zeuzem, Stefan
    SWISS MEDICAL WEEKLY, 2011, 141 : 3S - 3S
1234